{"entity":{"id":"nct05627856","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","aka":[],"tldr":"A phase 1/2 trial of GNC-038 in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL is a phase 1/2 interventional study registered as NCT05627856 by Sichuan Baili Pharmaceutical Co., Ltd., with 4 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-038.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05627856","url":"https://clinicaltrials.gov/study/NCT05627856"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05627856","phase":"1/2","setting":"An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":4,"outcomes":[]},"route":"/trials/nct05627856/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}